GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome
17y agoen
From the article
GSK & XenoPort have resubmitted NDA to the FDA for approval of Solzira Extended Release Tablets, treatment of moderate-to-severe primary RLS
Continue reading on GSKYou might also wanna read
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
clinicaltrials.gov·1d ago
EAN 2026: Positive trial data for cemdisiran underscores potential for use in generalized MG, says GlobalData
globaldata.com·8d ago
SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial
clinicaltrials.gov·7d ago
A Study to Investigate GSK5733584 as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
clinicaltrials.gov·3d ago
National Psoriasis Foundation Review Examines GLP-1 Receptor Agonists for Psoriasis with Metabolic Comorbidities
This review from the US National Psoriasis Foundation Medical Board provides an evidence-informed narrative synthesis on GLP-1 receptor agon
doi.org·1mo ago
Semaglutide Shows Chondroprotective Effects in Osteoarthritis Through Weight Loss-Independent Metabolic Mechanism
This research article demonstrates that semaglutide, a GLP-1 receptor agonist, provides chondroprotective effects in osteoarthritis mouse mo
cell.com·4mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.